Forepont Capital Partners

Forepont Capital Partners

Bernard Davitian founded Forepont Capital Partners in 2017, establishing the firm in New York to invest at the intersection of academic research and clinical application. Davitian structured it as a dedicated healthcare and life sciences venture platform, targeting early-stage companies translating scientific discovery into therapeutic and diagnostic products. The firm operates across the U.S. and Europe, maintaining a thesis grounded in the conviction that university-originated innovation remains the most undercapitalized source of venture-grade medical returns. Forepont's deployment spans biotechnology, medical devices, and digital health, with a preference for Series A and early-growth rounds. It typically leads or co-leads rounds, syndicating selectively with specialist healthcare investors and corporate venture arms. Confirmed portfolio positions, per public records, include AviadoBio, a gene therapy company targeting frontotemporal dementia, and Moon Surgical, a French-American developer of robotic surgery platforms. The firm also backs digital health infrastructure, with investments such as Kiro, an AI-driven clinical laboratory results platform. Deal activity is evenly split between U.S. East Coast clusters and Western European hubs, particularly Paris and London. The firm maintains a lean partnership structure centered on Davitian, who previously held operating and investment roles in the European medtech sector. Forepont has not publicly disclosed firm-wide AUM or team headcount. In May 2024, the firm participated in Moon Surgical's $55M Series B extension alongside Sofinnova Partners and other syndicate members, deepening its commitment to capital-efficient surgical robotics companies (per public regulatory filings, 2024). Adjacent vehicles, including any philanthropic or foundation structures, have not been publicly identified. Forepont's structural differentiator is its deliberate calibration between bench science and market access. Unlike generalist venture firms that opportunistically enter healthcare, the partnership's sourcing relies on direct relationships with technology transfer offices at major research universities on both sides of the Atlantic. This gives the firm a persistent look at pre-diligenced assets before they reach broader auction, effectively compressing the competitive window for specialized European and U.S. East Coast biotech deal flow.